Englander Institute for Precision Medicine

Publications

Found 719 results
Author Title Type [ Year(Asc)]
2024
Guillet S, Lazarov T, Jordan N, Boisson B, Tello M, Craddock B, Zhou T, Nishi C, Bareja R, Yang H et al..  2024.  ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis.. medRxiv.
Lira MCecilia, Vanpouille-Box C, Galluzzi L.  2024.  Adaptive inhibition of CGAS signaling by TREX1.. Trends Cancer. 10(3):177-179.
San Pedro JManuel Bra, Aranda F, Buqué A, Galluzzi L.  2024.  Animal models of disease: Achievements and challenges.. Methods Cell Biol. 188:xv-xxi.
Stenzl A, Armstrong AJ, Sboner A, Ghith J, Serfass L, Bland CS, Schijvenaars BJA, Sternberg CN.  2024.  Artificial INtelligence to Support Informed DEcision-making (INSIDE) for Improved Literature Analysis in Oncology.. Eur Urol Focus.
De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C.  2024.  Author Correction: Cancer cell metabolism and antitumour immunity.. Nat Rev Immunol.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2024.  Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 15(1):225.
Sridhar SS, Powles T, Durán MÁCliment, Park SHoon, Massari F, Thiery-Vuillemin A, Valderrama BP, Ullén A, Tsuchiya N, Aragon-Ching JB et al..  2024.  Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.. Eur Urol. 85(2):154-163.
Shah Y, Kulm S, Nauseef JT, Chen Z, Elemento O, Kensler KH, Sharaf RN.  2024.  Benchmarking multi-ancestry prostate cancer polygenic risk scores in a real-world cohort.. PLoS Comput Biol. 20(4):e1011990.
De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C.  2024.  Cancer cell metabolism and antitumour immunity.. Nat Rev Immunol.
Kepp O, Galluzzi L, Petroni G.  2024.  Cellular senescence and aging at the crossroad between immunity and cancer.. Methods Cell Biol. 181:xvii-xxiv.
Vitale I, Galassi C, Galluzzi L.  2024.  Chromosomal instability drives immunosuppression and metastatic dissemination.. Cell Res. 34(1):7-8.
Kasi PM, Lee JK, Pasquina LW, Decker B, Borre PVanden, Pavlick DC, Allen JM, Parachoniak C, Quintanilha JCF, Graf RP et al..  2024.  Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.. Clin Cancer Res. 30(4):836-848.
Agarwal PK, Sternberg CN.  2024.  Clinical Trials Corner Issue 10(1).. Bladder Cancer. 10(1):83-87.
Meleshko D, Prjbelski AD, Raiko M, Tomescu AI, Tilgner H, Hajirasouliha I.  2024.  cloudrnaSPAdes: isoform assembly using bulk barcoded RNA sequencing data.. Bioinformatics. 40(2)
Li S, Wong A, Sun H, Bhatia V, Javier G, Jana S, Wu Q, Montgomery RB, Wright JL, Lam H-M et al..  2024.  A combinatorial genetic strategy for exploring complex genotype-phenotype associations in cancer.. Nat Genet. 56(3):371-376.
Izadmehr S, Fernandez-Hernandez H, Wiredja D, Kirschenbaum A, Lee-Poturalski C, Tavassoli P, Yao S, Schlatzer D, Hoon D, Difeo A et al..  2024.  Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis.. bioRxiv.
Siew K, Nestler KA, Nelson C, D'Ambrosio V, Zhong C, Li Z, Grillo A, Wan ER, Patel V, Overbey E et al..  2024.  Cosmic kidney disease: an integrated pan-omic, physiological and morphological study into spaceflight-induced renal dysfunction.. Nat Commun. 15(1):4923.
Lira MCecilia, Galluzzi L, Vanpouille-Box C.  2024.  COX2-dependent suppression of anticancer immunity.. Trends Cancer.
Noch EK, Palma L, Yim I, Bullen N, Barnett D, Walsh A, Bhinder B, Benedetti E, Krumsiek J, Gurvitch J et al..  2024.  Cysteine induces mitochondrial reductive stress in glioblastoma through hydrogen peroxide production.. Proc Natl Acad Sci U S A. 121(8):e2317343121.
Klomp JE, J Diehl N, Klomp JA, A Edwards C, Yang R, Morales AJ, Taylor KE, Drizyte-Miller K, Bryant KL, Schaefer A et al..  2024.  Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.. Science. 384(6700):eadk0850.
Greenberg JA, Shah Y, Ivanov NA, Marshall T, Kulm S, Williams J, Tran C, Scognamiglio T, Heymann JJ, Lee-Saxton YJoo et al..  2024.  Developing a predictive model for metastatic potential in pancreatic neuroendocrine tumor.. J Clin Endocrinol Metab.
Risnik D, Colado A, Podaza E.  2024.  Editorial: Myeloid cell reprogramming: molecular pathways involved in disease development.. Front Immunol. 15:1414482.
Shore ND, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Tombal B, Nordquist L, Cookson M, Verholen F et al..  2024.  Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.. Oncologist. 29(3):235-243.
Mack TM, Raddatz MA, Pershad Y, Nachun DC, Taylor KD, Guo X, Shuldiner AR, O'Connell JR, Kenny EE, Loos RJF et al..  2024.  Epigenetic and proteomic signatures associate with clonal hematopoiesis expansion rate.. Nat Aging.
Ohara K, Rendeiro AFigueiredo, Bhinder B, Eng KWha, Ravichandran H, Nguyen D, Pisapia D, Vosoughi A, Fernandez E, Shohdy KS et al..  2024.  The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.. Nat Commun. 15(1):2009.